Thus, HIF-1α and NF-κB may be candidate molecular targets for gastric cancer therapy, and in particular, blocking the NF-κB/HIF-1α pathway with appropriate inhibitors might be useful therapeutically for treating gastric carcinoma. The gene discussed is HIF1A; the disease is gastric carcinoma.